Boston Scientific (BSX) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting ...

The stock's fall snapped a six-day winning streak.

Boston Scientific is currently sporting a Zacks Rank of #2 (Buy). Over the past 90 days, the Zacks Consensus Estimate for BSX's full-year earnings has moved 2.3% higher.

With a market cap of $154.3 billion, Boston Scientific Corporation (BSX) is a global developer, manufacturer, and marketer of ...

Boston Scientific’s Operating Cash Flow (OCF) for the same period was $3.8 billion, indicating a good OCF margin of 21.7% compared to the S&P 500’s 14.9%.

Boston Scientific, one of the largest medical technology companies in the nation, is vacating its Minnetonka campus for good in one year, the listing said, opening up 24 acres for sale. The ...

Revenue Growth: Boston Scientific displayed positive results in 3M. As of 31 March, 2025, the company achieved a solid revenue growth rate of approximately 20.93%.

Boston Scientific Corporation (NYSE:BSX) is one of the best stocks to buy. On June 10, the company announced that it is ...

Boston Scientific (BSX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Boston Scientific Corporation (NYSE:BSX) is one of the best stocks to buy. On June 10, the company announced that it is selling one suburban Twin Cities property and expanding another, mirroring a ...

Boston Scientific BSX has delivered an impressive return over the past year, with shares rallying 40.5%. The performance outpaced the industry’s 14.3% gain and the S&P 500 composite’s 12.5% rise.

Boston Scientific agreed to pay Johnson & Johnson $600 million in connection with Johnson & Johnson’s botched acquisition of Guidant, a medical device company, in 2004. By David Gelles DealBook ...